Objective:Hepatocellular carcinoma (HCC) is a major global public health burden,which is the third leading cause of cancer-related deaths worldwide.As is well known,chronic hepatitis B (CHB) can lead to the development of HCC.Currently,emerging data demonstrated that antiviral treatments could reduce the incidence of HCC,but also prevent or delay recurrence.